Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of pulmonary hypertension as a cause of mortality in sickle cell disease (SCD) is controversial. METHODS AND RESULTS: We evaluated the relationship between an elevated estimated pulmonary artery systolic pressure and mortality in patients with SCD. We followed patients from the walk-PHaSST screening cohort for a median of 29 months. A tricuspid regurgitation velocity (TRV)≥ 3.0 m/s cuttof, which has a 67-75% positive predictive value for mean pulmonary artery pressure ≥ 25 mm Hg was used. Among 572 subjects, 11.2% had TRV ≥ 3.0 m/sec. Among 582 with a measured NT-proBNP, 24.1% had values ≥ 160 pg/mL. Of 22 deaths during follow-up, 50% had a TRV ≥ 3.0 m/sec. At 24 months the cumulative survival was 83% with TRV ≥ 3.0 m/sec and 98% with TRV < 3.0 m/sec (p < 0.0001). The hazard ratios for death were 11.1 (95% CI 4.1-30.1; p < 0.0001) for TRV ≥ 3.0 m/sec, 4.6 (1.8-11.3; p = 0.001) for NT-proBNP ≥ 160 pg/mL, and 14.9 (5.5-39.9; p < 0.0001) for both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL. Age > 47 years, male gender, chronic transfusions, WHO class III-IV, increased hemolytic markers, ferritin and creatinine were also associated with increased risk of death. CONCLUSIONS: A TRV ≥ 3.0 m/sec occurs in approximately 10% of individuals and has the highest risk for death of any measured variable. The study is registered in ClinicalTrials.gov with identifier: NCT00492531.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with higher rates of hemolysis have lower steady-state Hb levels and are more likely to develop vascular injury and organ dysfunction as they age, manifesting as pulmonary hypertension, diastolic left heart disease, and renal dysfunction (proteinuria, albuminuria, and chronic kidney dysfunction) (62, 64, 65, 70, 79).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NT-proBNP, a prepro hormone released from cardiac myocytes of the left and right ventricles in response to pressure overload and wall stress, also identifies patients at higher risk of having pulmonary hypertension, with lower exercise capacity and increased mortality risk.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [62]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Self-citationRees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationWriting Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Self-citationA Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease
Parent, F., Bachir, D., Inamo, J., Lionnet, F., Driss, F., Loko, G., Habibi, A., Bennani, S., Savale, L., Adnot, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005565 · Cited by 512
Pulmonary Complications of Sickle Cell Disease
Gladwin, M. T., & Vichinsky, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0804411 · Cited by 470
Self-citationMortality in Sickle Cell Disease
(1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311515 · Cited by 459
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298 · cited 2×
“We also observed associations with mortality for two separate biomarkers of pulmonary hypertension, TRV and NT-proBNP, both of which were identified as risk factors for death in other cohorts [3–5,13].”
BackgroundPulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease
Fonseca, G. H. H., Souza, R., Salemi, V. M. C., Jardim, C. V. P., & Gualandro, S. F. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00134410 · Cited by 274
Cited by
Items 101–144 of 144
Valeshabad, A. K., Wanek, J. M., Molokie, R. E., Machado, R. F., Gordeuk, V. R., & Shahidi, M. (2015) · Clinical Case Reports · doi:10.1002/ccr3.439 · Cited by 4
Self-citationHydroxyureaTherapy in Patients with Sickle Cell Disease
(2015) · Translational Medicine · doi:10.4172/2161-1025.1000145 · Cited by 3
Chatel, B., Bernit, E., Vilmen, C., Michel, C. P., Bendahan, D., & Messonnier, L. A. (2020) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00790.2020 · Cited by 3
Sickle Cell Disease: From Ancient Origins to Modern Breakthroughs in Gene Therapy
Ikolo, B. T., Oyelami, M., Mgbeke, O. E., Jones, K., Thomas, S., & Ikolo, F. (2026) · Biomedicines · doi:10.3390/biomedicines14071649 · Cited by 2
Assessing the atria in pediatric sickle cell disease: Beyond the dilation
Loar, R. W., George, A., Varghese, N. P., Liu, A. M., Colquitt, J. L., & Pignatelli, R. H. (2020) · Echocardiography · doi:10.1111/echo.14956 · Cited by 2
Wilson, S. (2023) · The Hematologist · doi:10.1182/hem.v20.5.202351 · Cited by 2
Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature
Harrington, J. K., & Krishnan, U. (2019) · Current Pediatrics Reports · doi:10.1007/s40124-019-00188-3 · Cited by 2
Pulmonary hypertension and right ventricular function in the sickle cell populace
Oni, O. O., Adebiyi, A. A., Aje, A., & Akingbola, T. S. (2022) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_39_21 · Cited by 2
Joye, R., Wacker, J., Nguyen, D.-A., Hachulla, A.-L., Maggio, A. B. R., Cimasoni, L., Lador, F., Ansari, M., & Beghetti, M. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1221977 · Cited by 2
Pulmonary Complications of Hematologic Diseases
Machado, R. F., & Gladwin, M. T. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00094-4 · Cited by 2
Self-citationPulmonary Hypertension Among Individuals Living With Hemoglobinopathies: A Systematic Review
Okeke, C. C., Ojo, A., Okere, M. O., Ebiliekwe, O. E., Ekeocha, I. R., Idion, K. N., Egemonye, O., Alli, O. O., Ugo-Ihanetu, E. A., Okorienta, S., et al. (2025) · Cureus · doi:10.7759/cureus.88234 · Cited by 1
Babu, V., Little, J. A., Morris, C. R., Machado, R. F., Gibbs, S., Kato, G. J., Gordeuk, V. R., Gladwin, M. T., Zhang, Y., & Nouraie, S. M. (2025) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.70019 · Cited by 1
Self-citationThe burden of iron overload in sickle cell disease: insights from South Carolina, USA.
Vizcaíno, G., Abrams, C. M., Foster, C. B., Florez, H. J., Davila, N., & Rainey, S. (2025) · Investigación Clínica · doi:10.54817/ic.v66n4a03 · Cited by 1
Bertolet, M., Triulzi, D. J., Campbell‐Lee, S. A., Gordeuk, V. R., Herbert, B. M., Enrico, N., Jonassaint, C. R., Villanueva, F. S., Chien, N., Gladwin, M. T., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107542 · Cited by 1
Self-citationOgutu, B. R., Oyieko, J. N., Bello‐Manga, H., Akinsete, A. M., Githanga, J. N., Meneses, J. V. L., Hoppe, C. C., Davis, M. W., Rupon, J. W., Yu, C., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70856 · Cited by 1
Sickle Cell Anemia; 3 Years Clinical Experience in Bisha, Saudi Arabia (2010-2013)
Aziz, Y., Musharraf, W., Shah, S. I. H., & Tayeb, M. (2017) · INTERNATIONAL JOURNAL OF ENDORSING HEALTH SCIENCE RESEARCH (IJEHSR) · doi:10.29052/ijehsr.v5.i1.2017.10-15 · Cited by 1
The Myriad Presentations of Sickle Cell Disease-Related Pulmonary Hypertension
Prohaska, C. C., & Machado, R. F. (2021) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-20.2.46 · Cited by 1
Self-citationThe association between renal function decline and disease severity in sickle cell disease
Gaartman, A. E., Tuijn, C. F. J. V., Nur, E., Vogt, L., & Biemond, B. J. (2023) · American Journal of Hematology · doi:10.1002/ajh.26860 · Cited by 1
Correlates of nocturnal hypoxemia in children with sickle cell disease
Rani, S., Mahon, B., Afolabi‐Brown, O., Bernstein, B. A., Apollonsky, N., & Miller, R. E. (2024) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoae013 · Cited by 1
Curtis, S. A., Etzion, Z., Danda, N., Cohen, H. W., & Billett, H. H. (2014) · Blood · doi:10.1182/blood.v124.21.4070.4070 · Cited by 1
Mechanisms of complement activation under hemolytic conditions
Merle, N. S. (2017) · theses.fr (ABES) · doi:10.70675/0aebfdf4zf038z46a9z91a3z80b156fe114a
Sickle cell disease: Pathogenesis and biomarkers
Schimmel, M. (2017) · Pure Amsterdam UMC
Psychotherapy with the neurologically impaired.
Riscalla, L. M. (1978) · PubMed
Hereditary anemias: more complex than ever
van Vuren, A. J. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/429
Biomarcadores cardíacos em pacientes adultos com doenças falciformes
Fonseca, G. H. H. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2022.tde-12042023-152235
Hypertensive emergency versus preeclampsia in a patient with sickle cell disease: a case report
Patel, J., Reyes, J. E. P., Berezowski, I., Tran, Q. K., Frasure, S. E., & Pourmand, A. (2023) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.1920-8642.2023.060
Sickle cell disease: causes, treatments and the patient experience
Spurway, A., George, S., Thompson, C., Weeks, S., & Teo, X. Y. (2024) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2023.1.205570
Barnett, C. F., Brusca, S. B., Kolaitis, N. A., & Marco, T. D. (2024) · Current Respiratory Medicine Reviews · doi:10.2174/011573398x283197240222113135
Jerke, M., Bloch, W., Sportmedizin, D. S. K. I. F. K. U., & Herter, J. M. G. A. (2021) · Informationszentrum Lebenswissenschaften (ZB MED) · doi:10.4126/frl01-006426664
Assessment of renal function in pacientes with sickle cell anemia.
Cruz, S. M. P. [. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Sickle cell disease:From clinical challenges to therapeutic horizons
Gaartman, A. E. (2024) · UvA-DARE (University of Amsterdam)
Hydroxyurea: Why and how to use it to treat young patients with sickle cell anemia
Pondarré, C., & Soulié, A. (2023) · Cairn.info · doi:10.1684/hma.2023.1826
AbuAlhommos, A. K., Hawaj, M. A. A., Albader, B., Alsayyah, F. F., Aldakhil, F., Alrashed, F. S., & Ali, R. J. A. (2026) · Medicine · doi:10.1097/md.0000000000047728
New therapeutic strategies to treat delayed wound healing
Ngô, Q. T. (2024) · theses.fr (ABES) · doi:10.70675/5da2c033zf10bz4268zb777z5b352252e5b4
Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease
Zhang, X., Shah, B. N., Han, J., Nouraie, M. S., Zhang, Y., Machado, R. F., Gladwin, M. T., Saraf, S. L., & Gordeuk, V. R. (2026) · British Journal of Haematology · doi:10.1111/bjh.70517
Self-citationMcCuskee, S., Liu, Z., Lee, H.-C., Duran, L. M., Bellis, J., Haq, A., Curtis, S. A., Liu, A., Chui, T. Y. P., ROSEN, R., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017513
The Dilemma of Fluid Management in Acute Kidney Injury During Sickle Cell Crises: A Case Report
Ajite, A. B., Ogundare, E. O., Fasanmi, A., & Ilori, B. F. (2026) · Global Journal of Medical and Clinical Case Reports · doi:10.17352/gjmccr.000255
Pivert, C., Vasseur, L., Jestin, M., Flamarion, E., Guitton, C., Etienne‐Julan, M., Chamouine, A., Cimasoni, L., Dichamp, C., Kamden, A., et al. (2026) · HemaSphere · doi:10.1002/hem3.70434
Maternal and fetal outcomes in sickle cell disease: impact of anemia and prophylactic transfusion
Attah, A., Nwachukwu, N., Tfaily, M. A., Njoku, M., Aurora, T., Yoo, J., McLemore, M. L., Fasano, R., & Rassi, F. A. E. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100122
Shamavu, G. K., Nduwimana, M., Mseza, B., Vahwere, B. M., Hakizimana, T., Muhumuza, J., Elfakey, W. E., & Ndeezi, G. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1891576
Shaybah, M. E., Alsehli, O., Al-Harthi, A., Bajuaifer, N., Bafaqih, M., Alzhrani, M., Alasmari, A., Kashgari, A., Alhazmi, O., & Munshi, A. S. (2026) · Medicina · doi:10.3390/medicina62091731
Advancing mortality risk prediction in sickle cell disease through multi-task deep learning models
Lin, G., Tian, X., Asomaning, N., Conrey, A. K., Wu, C. O., Miao, R., & Thein, S. L. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020497
Joye, R., Wacker, J., Nguyen, D.-A., Hachulla, A.-L., Maggio, A. B. R., Cimasoni, L., Lador, F., Ansari, M., & Beghetti, M. (2023) · doi:10.3389/fped.2023.1221977.s001
Metadata
- Authors
- Gladwin, M. T., Barst, R. J., Gibbs, J. S. R., Hildesheim, M., Sachdev, V., Nouraie, M., Hassell, K. L., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., Novelli, E., Girgis, R. E., Morris, C. R., Berman Rosenzweig, E., Badesch, D. B., Lanzkron, S., Castro, O. L., Taylor, J. G., Goldsmith, J. C., Kato, G. J., Gordeuk, V. R., Machado, R. F., & on behalf of the walk-PHaSST Investigators and Patients
- Affiliations
- University of Pittsburgh (US)
- Columbia University (US)
- Imperial College London (GB)
- National Heart, Lung, and Blood Institute (US)
- Howard University (US)
- University of Colorado Denver (US)
- Case Western Reserve University (US)
- University of Illinois Chicago (US)
- Johns Hopkins University (US)
- Emory University (US)
- National Institutes of Health (US)
- Corresponding author
- Gladwin, Mark T.
- ORCID
- Gladwin, Mark T.
- Gibbs, J. Simon R.
- Sachdev, Vandana
- Nouraie, Mehdi
- Hassell, Kathryn L.
- Little, Jane A.
- Schraufnagel, Dean E.
- Krishnamurti, Lakshmanan
- Novelli, Enrico
- Girgis, Reda E.
- Morris, Claudia R.
- Lanzkron, Sophie
- Castro, Oswaldo L.
- Taylor, James G.
- Goldsmith, Jonathan C.
- Kato, Gregory J.
- Gordeuk, Victor R.
- Machado, Roberto F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-02
- Volume
- 9
- Issue
- 7
- Pages
- e99489
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4079316
- OpenAlex
- W2121881033
- Cited by
- 132
- References
- 23
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 16 · 2019: 13 · 2018: 7 · 2017: 8 · 2016: 13 · 2015: 12 · 2014: 2
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- U.S. Department of Health and Human Services
- American Society of Hematology
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Gilead Sciences
- Ikaria
- United Therapeutics Corporation
- Bayer Corporation
- Hemophilia Center of Western Pennsylvania
- International Union Against Tuberculosis and Lung Disease
- National Institutes of Health
- U.S. Public Health Service (HHSN268200617182C)
- National Heart, Lung, and Blood Institute (P01HL103455, HHSN268200617182C, R01HL111656, K23HL083089)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- sickle cell disease, mortality risk factors, pulmonary hypertension, tricuspid regurgitation velocity, NT-proBNP, mean pulmonary artery pressure, survival, chronic transfusion, hemolysis, ferritin, creatinine
- MeSH terms
- Adult, Anemia, Sickle Cell, Blood Flow Velocity, Blood Pressure, Creatinine, Female, Ferritins, Follow-Up Studies, United Kingdom, Hemolysis, Humans, Hypertension, Pulmonary, Male, Middle Aged, Peptide Fragments, Risk Factors, Severity of Illness Index, United States, Cohort Studies, Proportional Hazards Models, Walking, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.